Head and Neck Cancer
Health Information Search Results
Peer Reviewed Scientific Research Reports.
|<< Prev 20 ||Showing 1 to 20 of 20 Matches||Next 20 >>|
1. Exercise therapy for trismus in head and neck cancer.
Match Strength: 14.799
The aim of this study was to analyze retrospectively effects of exercise therapy on trismus related to head and neck cancer or as a consequence of its treatment, and to compare these effects with trismus not related to head and neck cancer. Medical records of patients referred to the department of physical therapy with the diagnosis trismus were retrieved and analyzed. Data of 27 patients with trismus related to head and neck cancer and data of eight patients with trismus not related to cancer were found. The number and type of exercises were registered from the records, as was the extent of ... Read More »
» Published in Oral Oncol. 2006 Sep 15;
2. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer.
Match Strength: 11.435
PURPOSE: Advanced head and neck cancer shows hypoxia that results in biological changes to make the tumor cells more aggressive and less responsive to treatment resulting in poor survival. [F-18] fluoromisonidazole (FMISO) positron emission tomography (PET) has the ability to noninvasively quantify regional hypoxia. We investigated the prognostic effect of pretherapy FMISO-PET on survival in head and neck cancer. EXPERIMENTAL DESIGN: Seventy-three patients with head and neck cancer had pretherapy FMISO-PET and 53 also had fluorodeoxyglucose (FDG) PET under a research protocol from April 1994 ... Read More »
» Published in Clin Cancer Res. 2006 Sep 15;12(18):5435-41. Comment in: Clin Cancer Res. 2006 Sep 15;12(18):5260-4.
3. A pilot study of chlorhexidine and benzydamine oral rinses for the prevention and treatment of irradiation mucositis in patients with head and neck cancer.
Match Strength: 10.848
This pilot study was designed to compare the efficacy of 0.2% wt/vol chlorhexidine gluconate and 0.15% wt/vol benzydamine hydrochloride oral rinses in alleviating irradiation oropharyngeal mucositis for patients with head and neck cancer. This was a prospective, randomized, and double-blinded study. Fourteen subjects were stratified based on nasopharyngeal cancer and non-nasopharyngeal head and neck cancer, and were randomly assigned to receive oral care protocol either containing with chlorhexidine (n = 7) or benzydamine (n = 7) from the first day to 2 weeks after the completion of ... Read More »
» Published in Cancer Nurs. 2006 Sep-Oct;29(5):423-30.
4. Epidermal growth factor receptor-targeted molecular therapeutics for head and neck squamous cell carcinoma.
Match Strength: 10.206
Several molecular-targeted therapeutics have been tested in clinical trials for the treatment of head and neck squamous cell carcinoma (HNSCC). Of these, therapeutics targeting the epidermal growth factor receptor (EGFR) have been studied most extensively and some agents have demonstrated measurable clinical effectiveness. However, molecular studies designed to define HNSCC patient subcohorts of likely responders to EGFR-targeted therapy have not identified molecular signatures that correlate with clinical response. Here, the authors summarise the relevant clinical findings and highlight ... Read More »
» Published in Expert Opin Ther Targets. 2006 Oct;10(5):639-47.
5. Professional delay in head and neck cancer patients: Analysis of the diagnostic pathway.
Match Strength: 9.893
The aim of this study was to identify which factors are related to specialist delay and to determine the length of the diagnostic pathway in head and neck cancer patients. Three hundred and six patients with a carcinoma of the larynx, pharynx or oral cavity were included in the study. Logistic regression analysis was used to identify risk factors for specialist delay. Large (T3-T4) tumors showed significantly less specialist delay than small (T1-T2) tumors (p=0.045, odds ratio [OR]=0.6). Pharyngeal (p=0.00, OR=0.2) and oral carcinomas (p=0.00, OR=0.2) had less specialist delay than glottic ... Read More »
» Published in Oral Oncol. 2006 Sep 25;
6. Rehabilitation of oral function in head and neck cancer patients after radiotherapy with implant-retained dentures: Effects of hyperbaric oxygen therapy.
Match Strength: 9.575
Surgical treatment of malignancies in the oral cavity and subsequent radiotherapy often result in an anatomic and physiological oral condition unfavorable for prosthodontic rehabilitation. The objective of this prospective study was to assess the effect of hyperbaric oxygen therapy on treatment outcome (condition of peri-implant tissues, implant survival, oral functioning and quality of life) of prosthodontic rehabilitation with implant-retained lower dentures in radiated head and neck cancer patients 6weeks and 1year after placing the new dentures. The treatment outcome was assessed in a ... Read More »
» Published in Oral Oncol. 2006 Sep 21;
7. Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck.
Match Strength: 8.452
PURPOSE: Alteration of the FAS/FAS ligand (FASLG) pathway regulating cell death may lead to cancer development, but the effects of functional promoter polymorphisms of the FAS and FASLG genes on risk of squamous cell carcinoma of the head and neck (SCCHN) are unknown. DESIGN: We genotyped the FAS -1377 G>A, FAS -670 A>G, FASLG -844 C>T, and FASLG IVS2nt -124 A>G polymorphisms in 721 case patients with SCCHN and 1,234 cancer-free non-Hispanic White control subjects frequency-matched by age and sex. Multivariate logistic regression was used to assess the adjusted odds ratios (OR) and ... Read More »
» Published in Clin Cancer Res. 2006 Sep 15;12(18):5596-602.
8. Audiometric patterns in ototoxicity of intra-arterial Cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Match Strength: 8.204
This study describes audiometric patterns of ototoxicity in a consecutive series of patients uniformly treated with intra-arterial high-dose cisplatin chemoirradiation for advanced cancer of the head and neck. Air conduction thresholds were measured from 0.125 to 16 kHz and bone conduction thresholds were measured from 0.5 to 4 kHz. The overall audiometric pattern was characterized by maximum threshold shifts after the 2nd cisplatin infusion and a maximum total threshold shift at 8 kHz, irrespective of gender, age, pretreatment sensorineural hearing loss (SNHL) or subjective complaints during ... Read More »
» Published in Audiol Neurootol. 2006;11(5):318-30. Epub 2006 Sep 18.
9. Intensity modulated radiation therapy: a review of current practice and future directions.
Match Strength: 7.791
The use of intensity modulated radiation therapy (IMRT) has been rapidly growing in the United States. This technology is now being used in a multitude of academic and community centers throughout the country and is being incorporated into the treatment of cancers in almost every anatomical site, most commonly head and neck cancer, central nervous system tumors, and prostate cancer. In addition, current protocols are investigating the use of IMRT for the treatment of breast cancer, lung cancer, abdominal/retroperitoneal malignancies, and gynecological diseases. This article presents a brief ... Read More »
» Published in Technol Cancer Res Treat. 2006 Oct;5(5):447-50.
10. Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancer.
Match Strength: 7.739
Purpose: Polymorphisms in DNA repair genes can influence response to radiotherapy. We analyzed single-nucleotide polymorphisms (SNP) in nine DNA repair genes in 108 patients with head-and-neck cancer (HNSCC) who had received radiotherapy only. Methods and Materials: From May 1993 to December 2004, patients with Stage I and II histopathologically confirmed HNSCC underwent radiotherapy. DNA was obtained from paraffin-embedded tissue, and SNP analysis was performed using a real-time polymerase chain reaction allelic discrimination TaqMan assay with minor modifications. Results: Patients were 101 ... Read More »
» Published in Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1022-30. Epub 2006 Sep 18.
11. Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies.
Match Strength: 7.662
PURPOSE OF REVIEW: The present review will describe progress in the utilization of epidermal growth factor receptor (EGFR) inhibitors in the treatment of nonsmall-cell lung cancer and the treatment of squamous cell carcinoma of the head and neck. Recent findings regarding clinical activity as well as markers associated with sensitivity to these agents will be reviewed. RECENT FINDINGS: The EGFR pathway plays a crucial role in human carcinogenesis by contributing to relevant processes in tumor development and progression, including cell proliferation, differentiation, regulation of apoptotic ... Read More »
» Published in Curr Opin Oncol. 2006 Nov;18(6):609-14.
12. Tumor ablation with photodynamic therapy: introduction to mechanism and clinical applications.
Match Strength: 7.072
Photodynamic therapy (PDT) has been used to treat cancer for more than 25 years. Although the focus has been primarily on surface or superficial lesions, there has been a rapid growth in its application to the treatment of deeper parenchymal malignancies. The photochemical reaction consists of a photosensitizer, which, when irradiated by light at a specific wavelength, generates a cytotoxic oxygen singlet. The end result is an efficient induction of cell death, primarily through apoptosis, microvascular damage, and an antitumor immune response. PDT is currently being used in the treatment of ... Read More »
» Published in J Vasc Interv Radiol. 2006 Sep;17(9):1441-8.
13. Frameless stereotactic radiosurgery for recurrent head and neck carcinoma.
Match Strength: 6.875
The aim of this study was to assess the feasibility and toxicity of stereotactic radiosurgery (CK-SRS) using the CyberKnife Frameless Radiosurgery System (Accuray Inc., Sunnyvale, CA) in the management of recurrent squamous cell carcinoma of the head and neck region (SCCHN). Between November 2001 and February 2004, 22 patients with recurrent, previously irradiated SCCHN were treated with CK-SRS. The following endpoints were assessed post-CK-SRS: local control (LC), cause-specific survival (CSS), overall survival (OS), symptom relief, and acute and late toxicity. Kaplan-Meier survival analyses ... Read More »
» Published in Technol Cancer Res Treat. 2006 Oct;5(5):529-35.
14. Use of topical misoprostol to reduce radiation-induced mucositis: results of a randomized, double-blind, placebo-controlled trial.
Match Strength: 6.653
Radiation-induced mucositis is an acute reaction of the mucosa of patients undergoing head and neck radiotherapy. It can have debilitating and dose-limiting consequences. There is no consensus on an accepted intervention that significantly reduces its severity. Misoprostol is a synthetic prostaglandin E1 analogue, with properties of a mucosal cytoprotectant. We designed a randomized, double-blind, placebo-controlled trial of misoprostol in patients with head and neck cancer. The aim of this study was to determine if topical misoprostol was effective in reducing the severity of radiation ... Read More »
» Published in Australas Radiol. 2006 Oct;50(5):468-74.
15. Complications encountered in a prospective series of 182 patients treated surgically for mouth cancer.
Match Strength: 6.566
Outcomes of surgical treatment for patients with mouth cancer can be limited by the risk of perioperative complications. This study identifies factors that predict for complications in such patients. Between 1992 and 2000, 182 patients had surgery for mouth cancer. The patient, their medical and surgical characteristics as well as perioperative complications were identified. Univariate analysis was carried out to determine which characteristics were associated with complications. Complications occurred in 85 patients (47%). Fifty-three percent of the complications were of intermediate severity ... Read More »
» Published in Oral Oncol. 2006 Sep 15;
16. Lymphatic mapping and sentinel node analysis: current concepts and applications.
Match Strength: 6.367
Since the introduction of sentinel node biopsy in 1990 as a minimally invasive surgical technique for the diagnosis of melanoma lymphatic metastases, the number of applications has expanded. We review applications and the current status of sentinel node biopsy in melanoma, breast, colon, gastric, esophageal, head and neck, thyroid, and lung cancer. Variations on techniques specific to each organ are explained, and the current role of sentinel node biopsy in diagnosis and treatment is discussed. Publication Types: ... Read More »
» Published in CA Cancer J Clin. 2006 Sep-Oct;56(5):292-309; quiz 316-7.
17. Incidental findings on integrated PET/CT that do not accumulate 18F-FDG.
Match Strength: 6.237
OBJECTIVE: The purpose of this study was to report the prevalence of abnormalities that do not show increased 18F-FDG uptake on the CT component of integrated PET/CT in patients with non-small cell lung cancer. MATERIALS AND METHODS: Images from all PET/CT studies performed consecutively between April and October 2003 on patients with non-small cell lung cancer were retrospectively reviewed. All abnormalities present on the CT component of the PET/CT scans that did not show abnormally increased 18F-FDG uptake were documented. RESULTS: Three hundred twenty-one patients with non-small cell lung ... Read More »
» Published in AJR Am J Roentgenol. 2006 Oct;187(4):1116-23.
18. Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen.
Match Strength: 5.391
PURPOSE: This study aims to identify a novel therapeutic agent for head and neck cancer and to evaluate its antitumor efficacy. EXPERIMENTAL DESIGN: A cell-based and phenotype-driven high-throughput screening of approximately 2,400 biologically active or clinically used compounds was done using a tetrazolium-based assay on FaDu (hypopharyngeal squamous cancer) and NIH 3T3 (untransformed mouse embryonic fibroblast) cells, with secondary screening done on C666-1 (nasopharyngeal cancer) and GM05757 (primary normal human fibroblast) lines. The "hit" compound was assayed for efficacy in combination ... Read More »
» Published in Clin Cancer Res. 2006 Sep 15;12(18):5557-69.
19. Re-engineering Primary Epithelial Cells from Rhesus Monkey Parotid Glands for Use in Developing an Artificial Salivary Gland.
Match Strength: 4.458
There is no satisfactory conventional treatment for patients who experience irreversible salivary gland damage after therapeutic radiation for head and neck cancer or because of Sjogren's syndrome. Additionally, if most parenchyma is lost, these patients also are not candidates for evolving gene transfer strategies. To help such patients, several years ago we began to develop an artificial salivary gland. In the present study, we used a non-human primate tissue source, parotid glands from rhesus monkeys, to obtain potential autologous graft cells for development of a prototype device for in ... Read More »
» Published in Tissue Eng. 2006 Sep 1;
20. Surgical management of locally advanced adenoid cystic carcinoma of the lacrimal gland.
Match Strength: 3.936
PURPOSE: To review our experience with multidisciplinary surgical management of locally advanced adenoid cystic carcinoma of the lacrimal gland. METHODS: We present a case series of 7 patients with lacrimal gland adenoid cystic carcinoma treated at our institution between June 2001 and October 2003. Clinical records, histologic sections, and radiographic images were reviewed. RESULTS: The study included 3 men and 4 women (mean age at diagnosis, 44 years). All 7 patients underwent an orbital exenteration with bone removal. Five patients had an orbitectomy through a craniotomy approach and 2 ... Read More »
» Published in Ophthal Plast Reconstr Surg. 2006 Sep-Oct;22(5):366-70.
|<< Prev 20 ||Showing results 1 to 20 of 20||Next 20 >>|
* All information on Level1Diet.com is for educational purposes only. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Before changing your diet, or adding supplements to your diet, or beginning an exercise program, everyone should consult a qualified and licensed health practitioner; a physician, dietician or similar professional.